METTL3 and neoplasm: demonstrated that METTL3 inhibited anti-tumor immunity by promoting the m6A-BHLHE41-CXCL1/CXCR2 axis to recruit immunosuppressive MDSCs suppressing CD8 + T cells, thereby facilitating CRC progression (156).